Compounded Dual-Incretin Formulation
Compounded dual GIP / GLP-1 agonist, with cyanocobalamin or glycine
- Format
- Injectable
- Spec
- B12 or glycine co-formulation, multiple concentrations
- Sourcing
- FDA-registered 503A pharmacy
Specifications
Available Formulations
Compounded to order by our 503A pharmacy partner. This lists what can be prepared, and is not a dosing recommendation.
| Strength & size | Beyond-use date | Quantity per fill |
|---|---|---|
| 6 mg-500 mcg/mL (2 mL) (12 mg vial)B12 | 90 days | Max 2 vials |
| 12 mg-500 mcg/mL (2 mL) (24 mg vial)B12 | 90 days | Max 2 vials |
| 17 mg-500 mcg/mL (2 mL) (34 mg vial)B12 | 90 days | Max 2 vials |
| 22 mg-500 mcg/mL (2 mL) (44 mg vial)B12 | 90 days | Max 2 vials |
| 28 mg-500 mcg/mL (2 mL) (56 mg vial)B12 | 90 days | Max 2 vials |
| 33 mg-500 mcg/mL (2 mL) (66 mg vial)B12 | 90 days | Max 2 vials |
| 10 mg-500 mcg/mL (3 mL) (30 mg vial)B12 | 90 days | Max 2 vials |
| 10.5 mg-500 mcg/mL (5 mL) (52.5 mg vial)B12 | 90 days | Max 2 vials |
| 20 mg-500 mcg/mL (3 mL) (60 mg vial)B12 | 90 days | Max 2 vials |
| 30 mg-500 mcg/mL (6 mL) (180 mg vial)B12 | 90 days | Max 2 vials |
| 15 mg-2.5 mg/0.5 mL (2 mL) (60 mg vial)Glycine | 90 days | Max 2 vials |
| 15 mg-2.5 mg/0.5 mL (6 mL) (180 mg vial)Glycine | 90 days | Max 2 vials |
- Sterility
- Endotoxin and sterility tested per sterile batch
- Compounding standard
- USP <797> and <800>
- Pricing
- Available on verified account approval
Beyond-use dates are assigned at compounding per USP <795> and <797> and printed on each container label. Values here are a planning reference and may vary by formulation, container and storage. The shortest applicable limit always governs: assigned beyond-use date, product stability, in-use and puncture dating, prescribed directions, and pharmacist review.
Research Summary
Mechanism & Physiological Role
Dual agonist acting on both GIP and GLP-1 receptors, enhancing glucose-dependent insulin release, improving lipid handling, and inducing greater weight reduction than GLP-1 monotherapy in clinical trials.
Clinical & Research Applications
Discussed in the peer-reviewed literature in the context of weight management and dual-incretin metabolic research. 503A compounded formulations are prepared per individual patient prescriptions.
Scientific Publications
Peer-Reviewed References
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
New England Journal of Medicine · 2022 · PMID: 35658024
All compounded formulations are prepared by a licensed 503A sterile compounding pharmacy partner. Compounds are available to NPI-verified licensed practitioners only, per individual patient prescriptions in accordance with applicable state and federal law. Compounded medications are not FDA-approved. Pricing available upon verified account approval.
Ready to add Compounded Dual-Incretin Formulation to your protocol?
Compounded formulations are dispensed by our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, under a valid patient-specific prescription. Prefer a formal quote? Request formulation-specific pricing instead.